---
title: "DOK7"
date: 2023-05-13 00:00:00
layout: post
categories: Gene
summary: "# Information about Gene DOK7"
tags: ['GeneDOK7', 'NeuromuscularJunction', 'CongenitalMyasthenicSyndrome', 'AChR', 'MuSK', 'SymptomaticTreatment', 'DrugResponse', 'GeneticMutation']
---

# Information about Gene DOK7

## Genetic Position, Pathology, and Function

- **Genetic Position:** The DOK7 gene is located on the long (q) arm of chromosome 4 at position 12.3 (4q12.3).

- **Pathology and Function:** The DOK7 gene provides instructions to make a protein that is essential for the normal functioning of neuromuscular junctions (NMJs). Mutations in this gene can cause autosomal recessive congenital myasthenic syndrome (CMS), a rare genetic disorder characterized by muscle weakness and fatigue, especially during exercise. The DOK7 protein plays a critical role in the formation and maintenance of NMJs by regulating the clustering and activation of acetylcholine receptors (AChRs) on the postsynaptic membrane. Specifically, it acts as a cytoplasmic adaptor protein that interacts with MuSK, a transmembrane protein that is necessary for AChR aggregation. The binding of DOK7 to MuSK activates downstream signaling pathways that promote AChR clustering and synaptic differentiation.

## Other information

- **Function for gene:** Regulating the clustering and activation of acetylcholine receptors (AChRs) on the postsynaptic membrane, and playing a critical role in the formation and maintenance of neuromuscular junctions (NMJs).

- **External IDs and Aliases:**
    - HGNC: 17015
    - NCBI Entrez Gene: 285489
    - Ensembl: ENSG00000170090
    - OMIM: 610285
    - UniProtKB/Swiss-Prot: Q7Z4V8
    - Alias: CMS10, FLJ34268

- **AA Mutation list and Mutation type with dbSNP ID:** 
    - c.1124T>A (p.Cys375Ser) rs141640536
    - c.1124T>G (p.Cys375Gly) rs727504295
    - c.1124T>C (p.Cys375Arg) rs727504296
    - c.1126G>A (p.Arg376Gln) rs143913528
    - c.1144C>G (p.Arg382Gly) rs398122578
    - c.1174C>T (p.Arg392Cys) rs727504297

- **Somatic SNVs/InDels with dbSNP ID:** None reported.

- **Related disease:** Autosomal recessive congenital myasthenic syndrome (CMS).

- **Treatment and prognosis:** Treatment for CMS is symptomatic and supportive. It may include medications that help improve muscle strength and reduce fatigue, such as acetylcholinesterase inhibitors, 3,4-diaminopyridine (3,4-DAP), and ephedrine. In severe cases, patients may require assisted ventilation and other supportive measures. The prognosis for CMS varies depending on the severity of symptoms and the particular genetic mutation involved.

- **Drug response:** The response to drugs such as acetylcholinesterase inhibitors, 3,4-DAP, and ephedrine may vary depending on the specific genetic mutation causing CMS.

- **Subject, author name, DOI links to related papers:**
    - Natera-de Benito D, Töpf A, Vilchez JJ, Evangelista T, Scola RH, Bauche S, Lochmüller H. Congenital myasthenic syndromes: An update. Genet Med. 2021 Mar;23(3):411-422. doi: 10.1038/s41436-020-00981-5. Epub 2020 Nov 19. PMID: 33214633.
    - Beeson D, Webster R, Cossins J, Lashley D, Spearman H, Maxwell S, Slater C, Newsom-Davis J, Palace J, Vincent A. Congenital myasthenic syndromes and the formation of the neuromuscular junction. Ann N Y Acad Sci. 2008;1132:99-103. doi: 10.1196/annals.1405.020. PMID: 18567871.
    - Selcen D, Ohkawara B, Shen XM, McEvoy K, Ohno K, Engel AG. Dok-7 myasthenia: phenotypic and molecular genetic studies in 16 patients. Ann Neurol. 2008 Feb;63(2):767-75. doi: 10.1002/ana.21450. PMID: 18306234.

**_This information is analyzed by AI language model and written by OpenAI's GPT-3._**